Stefan Oelrich is a member of the Board of Management of Bayer AG and President of its Pharmaceuticals Division, headquartered in Berlin, Germany. Since being appointed to these roles in 2018, Stefan Oelrich has spearheaded a transformation of Bayer’s Pharmaceuticals business, focusing on key areas of healthcare innovation to improve the lives of patients.
Stefan Oelrich first joined Bayer AG in 1989, assuming leadership positions of increasing strategic importance in Latin America (Argentina, Uruguay), Europe (France, Belgium), and the United States. During a period spanning more than three decades, Stefan Oelrich has led a series of bold transformations, and also revitalized performance at country and divisional levels.
During Stefan Oelrich’s seven-year tenure at the pharmaceutical and healthcare company Sanofi, he led the organization’s Germany, Switzerland and Austria organizations, and then went on to build up Sanofi’s diabetes and cardiovascular business. Stefan Oelrich was appointed Executive Vice President Diabetes & Cardiovascular and Member of Sanofi’s Executive Committee in 2016.
Since 2020, Stefan Oelrich has been a Member of the Supervisory Board of Charité.
Since June 2023, Stefan Oelrich serves as First Vice-President for the European Federation of Pharmaceutical Industries and Associations (EFPIA), representing the biopharmaceutical industry operating in Europe.